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Objectives:We used immuhistochemistry and Western blot to study ﬁbrillar and non-ﬁbrillar collagens, colla-
gen metabolism, matricellular proteins and regulatory factors of the ECM remodeling in left ventricular (LV)
septum biopsies from 3 groups of patients with aortic valve stenosis (AS): (AS-1,n = 9): ejection fraction
(EF) N 50%; AS-2,(n=12): EF 30%–50%; AS-3,(n=9): EF b 30%). Samples from 8 hearts with normal LV function
served as controls.
Results: In comparisonwith controls, ﬁbrillar collagens I and III were progressively upregulated from compensat-
ed (AS-1) toward decompensated hypertrophy (AS-3). The collagenIII/collagen I ratio decreased 2-fold in the AS-
2 and AS-3 groups as compared with AS-1 and controls. Non-ﬁbrillar collagen IV was upregulated only in AS-3
patients, whereas collagen VI progressively increased from AS-1 to AS-3 group. Collagen synthesis in AS-3 was
shifted to collagen I, while thematuration/degradation level was shifted to collagen III. RECKwas downregulated
only in AS-3 patients.Matricellular proteins tenascin and osteopontinwere increased in all AS patients. However,
thrombospondin 1, 4 and CTGF were increased only in AS-3. Only AS-3 patients were characterized by increased
levels of TGFβ1 and downregulation of TGFβ3, TGFβ-activated kinase1 and Smad7. In contrast, Smad3 gradually
increased from AS-1 toward AS-3. Similar trend of changes was observed for TNFα-R1 and TNFα-R2, whereas
TNFα was diminished only in AS-2 and AS-3.
Conclusions: Distinct changes in ﬁbrillar collagen turnover, non-ﬁbrillar collagens, matricellular proteins and the
key regulatory proﬁbrotic and anti-ﬁbrotic factors of the myocardial ECM remodeling are involved in the transi-
tion from compensated to decompensated LV hypertrophy and HF in human patients with AS.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).orphogenetic protein 1; CNN, Cyr61, connective tissue growth factor, Nov; CTGF, connective tissue growth factor; EF, ejection
IHC, immunohistochemistry; ICTP, carboxyterminal telopeptide (degradation product of cross-linked collagen I); IIINP,
n III); MMP, matrix metalloproteinase; NYHA, New York Heart Association; LV, left ventricle; LVEDP, left ventricular end-
minoterminal propeptide of type-I procollagen (newly synthesized collagen I); PIIINP, N-terminal type III collagen peptide
oﬂuorescence; RECK, reversion-inducing cysteine-rich protein with Kazal morifs; Smad, small mother against decapentaplegic;
ST, Tris buffer saline Tween-20; TGFβ, transforming growth factor β; TIMP, tissue inhibitor of matrix metalloproteinases; TNFα,
α receptor 1; TNFα-R2, Tumor necrosis factor α receptor 2; TSP, thrombospondin; WB, Western blot.
Structural Biology, Max-Planck-Institute for Heart and Lung Research, Ludwigstrasse 43, 61231, Bad Nauheim, Germany.
in).
and Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Table 1
Clinical data.
Control
(n = 8)
AS-1
(n = 9)
AS-2
(n = 12)
AS-3
(n = 9)
Age, years 55.8 ± 9.8 64.3 ± 8.5 66.1 ± 8.2 67.2 ± 9.9
Men/women 6/2 5/4 5/7 6/3
NYHA (classes III–IV) 0 0 3 7 (77.8%)
EF, % N60% 59.5 ± 4.8 40.6 ± 6.4 24.3 ± 4.8
LV mass/m2 92.7 ± 12.2 130.5 ± 20.2 138.3 ± 11.7 145.2 ± 14.4
IVS (mm) 11 ± 0.8 15.1 ± 4.2 17.4 ± 4.6 19.8 ± 6.2
ΔP mean (mm Hg) – 65.2 ± 11.5 54.3 ± 14.9 42.8 ± 17.7
LVEDP 8 ± 1 14 ± 4 18 ± 5 23 ± 7
LVESP 130 ± 12 171 ± 17 165 ± 14 152 ± 15
LVEDD 49 ± 2 47 ± 6 48 ± 6 56 ± 6
LVESD 33 ± 3 30 ± 7 36 ± 6 42 ± 10
Diuretics, (n/%) – 0 3 (25%) 7 (77.8%)
Digitals, (n/%) – 0 1 (8.3%) 7 (77.8%)
ACE inhibitors, (n/%) – 2 (22.2%) 2 (16.7%) 2 (22.2%)
β-Blockers, (n/%) – 1 3 (25%) 3 (33.3%)
LVEDP, LV end-diastolic pressure; LVESP, LV end-systolic pressure; IVS, interventricular
septum; LVEDD, LV end-diastolic diamter; LVESD, LV end-systolic diamter; ΔP mean,
mean ventricular-aortic pressure gradient.
Table 2
List of antibodies.
Antibody Company Host WB/IHC
Collagen I Rockland Rabbit IHC
Collagen III Rockland Rabbit IHC
Collagen IV Rockland Rabbit IHC/WB
Collagen V Rockland Rabbit IHC/WB
Collagen VI Rockland Rabbit IHC/WB
BMP1 Oncogene Rabbit WB
RECK BD Biosciences Mouse WB
Osteonectin Santa Cruz Rabbit WB
Osteopontin Acris Rabbit WB
Tenascin Sigma Mouse IHC
Tenascin C R&D Rat IHC
TSP1 Calbiochem Mouse IHC/WB
TSP2 Santa Cruz Rabbit WB
TSP4 Santa Cruz Mouse WB
CTGF Santa Cruz Rabbit IHC
CTGF Abcam Rabbit WB
TGFβ1 Santa Cruz Rabbit WB
TGFβ2 Abcam Rabbit WB
TGFβ3 Abcam Rabbit WB
TAK1 Cell Signaling Rabbit WB
Smad1 Cell Signaling Rabbit WB
Smad2 Cell Signaling Mouse WB
Smad3 Cell Signaling Rabbit WB
Smad 7 Santa Cruz Rabbit WB
TAK1 Cell Signaling Rabbit WB
TNFα Sigma Mouse WB
TNFα-R1 Biovision Mouse WB
TNFα-R2 Abcam Rabbit WB
Actin (HHF35) Sigma Mouse WB
WB, Western blot, IHC, immunohistochemistry.
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Aortic valve stenosis (AS) is often associated with heart failure and
high mortality [1–3]. Myocardial remodeling is a determinant stage of
heart failure (HF), which is characterized by changes of ventricular
size, shape and function [4]. The process of left ventricular (LV) remod-
eling is accompanied by cardiomyocyte hypertrophy and loss, extracel-
lular matrix (ECM) reorganization and the increased ECM elements
[5–8]. Despite numerous studies, the exact cellular and molecular
mechanisms of cardiac remodeling in AS remain mostly unknown and
are limited mainly to experimental animal data [9–14]. We and others
have previously shown that the extent of ECM remodeling andmyocar-
dial ﬁbrosis may not be reversible after delayed AS surgery [3,5,15–17].
Therefore, detection of the structural and molecular components in-
volved in myocardial ECM remodeling could help to ﬁnd promising
therapeutic targets and prospective biomarkers to optimize the time
of aortic valve replacement.
The collagens are the most abundant proteins of the ECM and well-
accepted tissuemarkers of cardiac remodeling [18]. The adultmyocardi-
um consists of ﬁbrillar collagen type I and collagen type III [19]. Collagen
type V is another ﬁbrillar collagen that in humans is encoded by the
COL5A1 gene [20]. The distribution and expression of collagen V in the
normal or pathological heart are almost unknown.
Although collagen type I and III are themost prevalent inmyocardial
ECMand their role inmyocardial remodeling is increasingly studied, the
role of non-ﬁbrillar collagens such as collagen type IV andVI is less stud-
ied. Recently it was demonstrated that deletion of collagen VI in mice
has a protective effect after myocardial infarction by reducing ﬁbrosis
and pathological remodeling [21]. It is reasonable therefore to hypothe-
size that collagen VI is also involved in ECM remodeling in the hyper-
trophied heart.
The ﬁbrillar collagens are secreted into the ECM as N-terminal
propeptides PINP and PIIINP, carboxyterminal (ICTP) and aminoter-
minal telopeptides. PINP and PIIINP represent the newly synthesized
collagen I and collagen III, respectively. ICTP detects degraded collagen
I, whereas IIINTP is a marker of cross-linked mature collagen III [15,
22–25].
Collagen turnover is essential in ECM remodeling. Removal of c-
terminal propeptides of ﬁbrillar procollagens is a crucial event inFig. 1.Representative confocal micrographs of collagen type I (green) and type III (red) in contro
collagens from controls to AS-1, AS-2 and AS-3. Merged images (right panels) show the prevalen
the AS-2 and AS-3 groups, the quantity of both collagens is apparently equal. Nuclei are shown i
phalloidin. Lower diagrams represent quantitative data of collagen I, collagen III, and the collag
hibit signiﬁcantly lower collagen III/collagen I ratio in comparison with the AS-1 group and concollagen ﬁbril-formation and is accomplished by procollagen c-
proteinases which are identical to bone morphogenetic protein-1
(BMP1), a member of the tolloid family of Zn-dependent astacin-like
metalloproteinases [26]. Collagen turnover is regulated basically by ma-
trix metalloproteinases and their tissue inhibitors. A newly discovered
alternative inhibitor of matrixmetalloproteinases is RECK (reversion-in-
ducing cysteine-rich protein with Kazal morifs) [27]. However, neither
BMP1 nor RECK has been studied in relation to compensated or decom-
pensated myocardial hypertrophy.
Matricellular proteins have been classiﬁed as a family of non-
structural family of extracellular proteins that do not play primarily a
structural role in the ECM but inﬂuence collagen ﬁbril assembly [28].
The role of this protein family in myocardial remodeling in the hyper-
trophied and/or failing myocardium still remains obscure. As an exam-
ple, tenascin, thrombospondin-1 and 2, osteonectin and osteopontin are
highly expressed during embryogenesis and are very low or absent in
adult normal hearts. In contrast, during HF progression these proteins
appear to be up-regulated [29]. In addition, the role of connective tissue
growth factor in the heartwhich also belongs tomatricellular proteins is
limited to myocardial infarction [30].
Myocardial ECM remodeling is essentially regulated by proﬁbrotic
and anti-ﬁbrotic factors. Among them, an important role has TGF-β,
consisting of three highly conserved isoforms, designated TGFβ-1,
TGFβ-2, and TGFβ-3. From all these 3 isoforms, only TGFβ-1 has inten-
sively been studied in the pathological heart. Tumor necrosis factor-
alpha (TNFα) is another factor which is believed to be involved in the
regulation of ﬁbrosis [31]. However, more studies are needed to sub-
stantiate its role in ﬁbrosis, especially in the transition from compensat-
ed to decompensated cardiac hypertrophy.ls and in patients with AS demonstrating a gradual increase accumulation of these ﬁbrillar
ce of collagen III over that of collagen I in control and partially in AS-1 patients, whereas in
nwhite after stainingwith DAPI and F-actin is shown in blue after labelingwith Alexa633-
en III/collagen I ratio in control and in AS groups. Notice that the AS-2 and AS-3 groups ex-
trols.
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es in ﬁbrillar collagen turnover, non-ﬁbrillar collagens, matricellular
proteins and the key regulatory proﬁbrotic and anti-ﬁbrotic factors of
the ECM remodeling are involved in the transition from compensated
to decompensated LV hypertrophy and HF in human patients with AS.
2. Material and Methods
2.1. Patients
Thirty patients with isolated aortic valve stenosis were sub-
divided into three different groups on the basis of (LV) determinedFig. 2. Typical confocal images of collagen V (green) distribution in control and AS groups. Nuc
actin (HHF-35). For WB quantiﬁcation, collagen VI is normalized to sarcomeric actin and expre
creased only in decompensated hypertrophy (AS-3) in comparison with controls.echocardiographically at the time of admission: group I (AS-1) EF
N 50% (n = 9), group II (AS-2), EF 50%–30% (n = 12) and group III
(AS-3), EF b 30% (n = 9). All patients underwent surgical aortic
valve replacement. As previously described [5,15,32], based on clin-
ical and hemodynamic data (Table 1), the myocardium from the AS-1
group was regarded as representing compensated LV hypertrophy, the
AS-2 as the transitional stage and the AS-3 group as representing de-
compensated hypertrophy and the failing myocardium. Controls were
LV biopsies from 8 hearts with normal LV function. The institutional
Ethical Committee approved the study. All patients gave informed con-
sent. The investigation conforms with the principles outlined in the
Declaration of Helsinki.lei are stained blue with DAPI. Lower left panels are representative WB for collagen V and
ssed as percent of control values. Notice that the amount of collagen V is signiﬁcantly in-
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During aortic valve replacement, when a subaortic myocardial re-
section was performed, these samples from the LV septum were im-
mediately frozen in liquid nitrogen, and stored at −80 °C. Before
immunolabeling, tissue characterization and orientation were recorded
by hematoxylin and eosin staining. Frozen sections were ﬁxed for
15 min with 4% paraformaldehyde and then incubated with the primary
antibodies which are listed in Table 2. Anti-mouse or anti-rabbit IgG-
conjugatedwithCy3or Cy2 (Biotrend) served as detection systems in sin-
gle or double immunolabelings. The nuclei were stained with 1 μg/ml
4,6-diamidino-2-phenylindole (DAPI) (Molecular Probes). F-actin wasFig. 3. Confocal images of collagen IV (green) distribution in control and AS groups. Nuclei are
determined by QIF and expressed as percent of the signal per tissue area. Lower right panels ar
control and AS groups.ﬂuorescently stained using TRITC-conjugated (Sigma) or Alexa633-
conjugated phalloidin (Molecular Probes). Negative controls were
obtained by omitting the primary antibody, in an otherwise similar pro-
tocol. The samples were examined by confocal laser microscopy (Leica
TCS-2). Digital images were further processed for 3D-reconstruction
using software “Imaris” (Bitplane AG, Zürich, Switzerland).
2.3. Quantitative immunoﬂuorescent microscopy
Measurements of immunoﬂuorescence were done using ×40
Planapo objective (Leica) and a Leica (Leitz DMRB) ﬂuorescent micro-
scope equipped with a Leica DC380 digital camera. Cryosections fromstained blue with DAPI. The left lower diagram shows the quantitative data of collagen IV
e representative WB for collagen IV quantitative data of collagen IV normalized to actin in
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tive analysis all sections were immunolabeled simultaneously using
identical dilutions of primary and secondary antibodies and other re-
agents. Immunoﬂuorescent images were obtained under identical
parameters of imaging, zoom, pinholes, objectives, and ﬂuorescence
power. Sections exposed to PBS instead of primary antibodies served
as negative controls. One channel with the format of 1024 × 1024 pixels
and appropriate ﬁlters were used. The image acquisition settings were
standardized for all groups to ensure that the image collect-
ed demonstrated a full range of ﬂuorescence intensity from 0 to
255 pixel intensity level and were kept constant during all measure-
ments. For each patient at least 10 random ﬁelds of vision were ana-
lyzed for the quantity of the investigated markers using images
analysis software (Leica) and Image J program. The area occupied by dif-
ferent markers was calculated as percent of the signal per tissue area.
2.4. Western Blot
Samples were processed for Western blot analysis as previously de-
scribed [15,24]. In brief, frozen tissue was homogenized in RIPA buffer
(containing 20 mmol/l Tris–HCl at pH 7.4, 100 mmol/l NaCl, 5 mmol/l
thylene-diamine tetraacetic acid, 1% Triton X-100, 10% glycerol, 0.1% so-
dium dodecylsulfate, 1% deoxycholate, 50 mmol/l NaF, 10 mmol/l
Na4P2O7, 1 mmol/l Na3VO4, 1 mmol/l phenylmethylsulfonylﬂouride)
and mammalian protease inhibitor cocktail (Sigma) at pH 7.4 and cen-
trifuged at 2000×g at 4 °C for 10min. LVmyocardial extractswere load-
ed onto 12% polyacrylamide gel and separated under the reducing
conditions. Proteins were electrotransferred onto nitrocellulose mem-
brane (Invitrogen) and blocked with 5% non-fat dry milk in Tris-
buffered saline Tween-20 (TBST) at 4 °C. After washing with TBST,Fig. 4. Expression of collagen VI (green) in control and in patients with AS. Cardioproteins were exposed overnight at 4 °C to antibodies against MMP2
andMMP9 (Biotrend) diluted in TBSwith 5% powderedmilk. Bound an-
tibodies were detected by peroxidase-conjugated anti-mouse IgG
horseradish peroxidase-conjugated and SuperSignal WestFemto
(Pierce) detection system and exposed to X-ray ﬁlm. Quantiﬁcation of
immunoblots was done by scanning on a STORM 860 (Amersham
Pharmacia Biotech) using ImageQuant software. The immunoblotting
values for the investigated proteins were normalized per actin (clone
HHF-35, Sigma). The control values were set at 100% (see Fig. 2, as an
example).
2.5. Statistical analysis
All data are presented as means ± SD. For multiple comparisons
we used ANOVA, followed by analysis with the Bonferroni t-test. As-
sociations between variables were assessed using Spearman’s rank
correlation. Differences between groups were considered signiﬁcant at
p b 0.05.
3. Results
3.1. Fibrillar collagens
The typical localization, distribution and the amount of collagen I
and collagen III are shown in Fig. 1. In comparison with controls, both
collagens gradually increased in AS patients reaching the highest
amount in decompensated hypertrophy (AS-3). Quantitative immuno-
ﬂuorescence (QIF) conﬁrmed these observations and demonstrated sig-
niﬁcant upregulation of both, collagen I and collagen III in AS groups,
especially in the AS-2 and AS-3 groups (Fig. 1). The collagen III/collagenmyocytes are stained red with phalloidin. Nuclei are stained blue with DAPI.
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hypertrophy (the AS-1 group). This ratio was dramatically decreased in
the transition phase (AS-2) and reached 1.69± 0.46 in decompensated
hypertrophy and HF (AS-3).
Collagen type V is another ﬁbrillar collagen. Representative confocal
pictures of collagen V localization and distribution are shown in Fig. 2
and depict that ﬁbers formed by collagen V surround individual car-
diomyocytes and vessels. The most remarkable increase in collagen V
was observed in decompensated hypertrophy (AS-3). QIF showed
that collagen V occupied 5.1% + 2.1% area of the control tissue and
increased modestly by 25% and 34% in the AS-1 and AS-2 groups, re-
spectively. In the AS-3 group, collagen V was 14.7%+ 2.6% and differed
signiﬁcantly from AS-1, AS-2 and control values. Quantitative WB
showed that the quantity of collagen V was increased only in the AS-3
group (Fig. 2).
3.2. Non-ﬁbrillar collagens
Collagen IV is a typical non-ﬁbrillar collagen that forms a ﬁne net-
work surrounding individual cardiomyocytes and blood vessels. Fig. 3
compares the distribution and the amount of collagen IV in control
andAS groups. In the AS-2 andAS-3 groups, collagen IV showed a strong
tendency to form thick septa isolating individual cardiomyocytes. QIF
showed that collagen IV was signiﬁcantly increased in the AS-2 and
AS-3 groups. WB showed that collagen IV was signiﬁcantly increased
only in decompensated hypertrophy (AS-3 group).
Collagen VI is another non-ﬁbrillar collagen and representative con-
focal images of collagen VI in LV myocardial tissue in control and in AS
patients are shown in Fig. 4 and demonstrate that collagen VI isFig. 5. Collagen VI expression levels in control and in patients with AS. (A) QIF shows a gradual
pared to controls. (B) A typicalWB for collagen VI showing the total (upper band) and destructe
in control and AS patients.obviously increased in all AS groups. These observations were con-
ﬁrmed by QIF (Fig. 5A). Typical WB for collagen VI discriminates be-
tween total and destructed collagen VI (Fig. 5B). Quantiﬁcation of the
total collagen VI showed signiﬁcant increases in the AS-2 and AS-3
groups (Fig. 5C). However, the most remarkable differences between
groups were observed in the amount of the destructed collagen VI
(Fig. 5D).
3.3. Collagen metabolism
The level of newly synthesized collagen I as observed by PINP
immunolabeling was signiﬁcantly enhanced in the AS-2 and AS-3
groups as compared to control (Fig. 6). The level of cross-linked but
partly destructed collagen I as detected by ICTP immunolabeling was
the highest in the AS-1 group. In comparison with control, the level of
newly synthesized collagen III as indicated by PIIINP staining was the
highest in compensated hypertrophy (AS-1 group). In comparison
with the latter group, the levels of PIIINP showed a tendency to be di-
minished in the transition phase (AS-2 group) and in decompensated
hypertrophy (AS-3 group). The mature form of collagen III (IIINTP)
gradually increased from AS-1 to AS-3.
Calculation of collagen markers ratios presented in the Table 3
demonstrated a signiﬁcant prevalence of collagen I synthesis over its
degradation (PINP/ICTP ratio) in the AS-3 group as compared with
other groups. In contrast, synthesis of collagen III was much lower
than mature collagen III (PIIINP/IIINTP ratio) in the AS-3 group. These
changes led to the prevalence of collagen I synthesis over that of colla-
gen III (PINP/PIIINP ratio) which was more pronounced in decompen-
sated (AS-3) than in compensated hypertrophy (AS-1) or in control.increase in collagen VI per tissue area (expressed in %) from AS-1 to AS-3 patients as com-
d collagen VI (lower band). (C, D) Quantitative data of the total and destructed collagen VI
Fig. 6.Markers of collagenmetabolism. Representative immunoﬂuorescent images of PINP (green) demonstrating low expression in a control (upper left panel) andmarked expression in
a AS-3 patient (upper right panel). Cardiomyocytes are stained red with phalloidin. Nuclei are stained blue with DAPI. Diagrams showing QIF analysis of markers of collagen I (PINP and
ICTP) and of collagen III (PIIINP, IIINTP).
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cial event in collagen ﬁbril-formation and is accomplished by pro-
collagen C-proteinases which are identical to bone morphogeneticTable 3
Ratios of collagen metabolism markers in control and in patients with AS.
Ratios Control (n = 8) AS-1 (n = 9) AS-2 (n = 12) AS-3 (n = 9)
PINP/ICTP 1.12 ± 0.56 0.79 ± 0.39 1.25 ± 0.41b 1.85 ± 0.57a,b,c
PIIINP/IIINTP 3.26 ± 1.31 3.01 ± 1.06 1.51 ± 0.53a,b 0.62 ± 0.17aa,b,c
PINP/PIIINP 0.76 ± 0.27 0.57 ± 0.22 0.98 ± 0.23 1.57 ± 0.33a,b,c
ICTP/IIINTP 2.76 ± 0.88 1.87 ± 0.77 1.14 ± 0.39a,b 0.52 ± 0.14a,b,c
a Versus control.
b Versus AS-1.
c Versus AS-2.protein-1 (BMP1), a member of the tolloid family of Zn-dependent
astacin-like metalloproteinases. The level of BMP1was signiﬁcantly up-
regulated in all AS groups as revealed by WB (Fig. 7A).
The expression of RECK, an alternative inhibitor of MMPs, was
recently described in adult human hearts [24]. RECK is known as a pro-
tective agent of ECM. In comparisonwith controls, the AS-3 group of pa-
tientswith ASwas characterized by signiﬁcant downregulation of RECK,
whereas the AS-1 and AS-2 groups showed only a negligible upregula-
tion of RECK (Fig. 7B).
3.4. Matricellular proteins
Among ECM proteins there are a number of proteins, collectively
called matricellular proteins, that do not have a structural role but
Fig. 7. Representative WB and quantitative data of BMP1 and RECK.
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Tenascins belong to matricellular proteins. In the present study, by
performing immunostaining of serial sections we observed that total
tenascins co-localizes with tenascin C (Fig. 8A and B) in both, control
and AS myocardial tissues. QIF showed that both, total tenascins and
tenascin C, gradually increased from compensated to decompensated
hypertrophy (Fig. 8C and D).
Osteonectin and osteopontin are also typical matricellular proteins.
WB for osteonectin showed no differences between groups in the ex-
pression levels (Fig. 8E). Osteopontin-positive stainingwas found in en-
dothelial cells and some ﬁbroblast-like cells of human myocardium
(data not shown). By WB, both levels of osteopontin and osteopontin
cleaved by MMP were increased in all patients with LV hypertrophy
due to AS (Fig. 8F and G).
Matricellular protein thrombospondin 1 (TSP1) was immunohis-
tochemically absent or present in minor quantities in controls, whereas
in patients with AS it was dramatically increased (Fig. 9). WB analysis
showed that TSP1 levels were elevated in patients with AS, especially
in patients with decompensated hypertrophy (AS-3). The level of TSP2
was signiﬁcantly enhanced in the AS-2 and AS-3 groups (Fig. 9). We
analyzed also TSP4, although it doesn't belong to matricellular pro-
teins, but it is a member of the thrombospondins family of the ECM
glycorproteins. It was upregulated only in the AS-3 group indicating
that TSP4 is a reliable marker of ECM remodeling in decompensated
hypertrophy.
Connective tissue growth factor (CTGF) is a secretedmultifunctional
protein that belongs to the CNN-family and matricellular proteins. By
immunohistochemistry we observed in control samples that CTGF is ro-
bustly expressed as small dot-like structures,whereas in AS patients it is
abundantly expressed in the ECM (Fig. 10). Both, QIF andWB showed a
signiﬁcant upregulation of CTGF in the AS-3 group (Fig. 10).3.5. Proﬁbrotic and anti-ﬁbrotic regulatory factors
The myocardial remodeling is essentially regulated by equilibration
of proﬁbrotic and anti-ﬁbrotic factors. An important signiﬁcance in ECM
remodeling and especially in ﬁbrosis has TGFβ, consisting in three high-
ly conserved isoforms, designated TGFβ-1, TGFβ-2, and TGFβ-3. We
analysed all these isoform by WB and the results are shown in Fig. 11.
TGFβ-1 was found to be upregulated only in decompensated hypertro-
phy (AS-3). There were no differences between groups in theexpression level of TGFβ-2. TGFβ-3 was mostly downregulated in the
AS-3 group.
TGFβ acts mainly via activation of Smads signaling proteins or TGFβ
activated kinase (TAK1). There were no differences between groups in
the expression level of Smad1. As compared with controls, Smad2
was signiﬁcantly upregulated in the AS-2 and AS-3 groups. Smad3 grad-
ually was increased from compensated (AS-1) to decompensated hy-
pertrophy (AS-3). The inhibitory Smad protein - Smad7 was found to
be downregulated only in patients with decompensated hypertrophy
(AS-3). Similarly, TAK1 was mostly downregulated in the AS-3 group
(Fig. 11).
TNF-α was found signiﬁcantly decreased in the AS-2 and AS-3
groups as compared with the AS-1 and control groups (Fig. 12). TNF-α
exerts its effects by binding to speciﬁc receptors TNFα-R1 and TNFα-
R2. In comparison with controls, the expression levels of TNFα-R1
gradually increased from compensated (AS-1) to decompensated hy-
pertrophy (AS-3). TNFα-R2 was mostly elevated in myocardial tissue
of patients with decompensated hypertrophy (Fig. 12).
4. Discussion
4.1. Major ﬁndings
In our previous studies we have established that the transition from
compensated to decompensated hypertrophy and HF is accompanied
by MMP/TIMP imbalance and progressive ﬁbrosis [5,15,25]. In the
present study we have further analyzed the factors contributing to the
pathogenesis of ﬁbrosis. The summary of our results and the major dif-
ferences between compensated and decompensated hypertrophy are
listed in Table 4.
4.2. Collagens and collagen metabolism
Synthesis of collagen I as revealed by PINP expression was 3-fold
increased in patients with decompensated hypertrophy in comparison
with controls. In contrast, synthesis of collagen III in decompensated hy-
pertrophy did not differ signiﬁcantly from control hearts. These changes
in collagen I and III synthesis observed in decompensated hypertrophy
were in marked contrast to the corresponding markers of collagen I
and III degradation, ICTP and IIINTP, respectively. Therefore, increases
in collagen I synthesis and collagen III degradation are a hallmark of de-
compensated hypertrophy. Our immunohistochemical data showing a
Fig. 8.Matricelullar proteins, tenascin, osteonectin and osteopontin in the myocardium of patients with AS and controls. (A, B) Representative immunoﬂuorescent serial images of total
tenascin (green) and tenascin C (red) demonstrating their co-localization (arrows). (C, D) QIF data of tenascin and tenascin C expressed as percent per tissue area. (E) RepresentativeWB
and quantitative data of osteonectin. (F, G) RepresentativeWB for osteopontin showing the native (arrow) and cleaved byMMP (arrowhead) form of osteopontin and their quantiﬁcation.
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published observations of genes encoding these forms of collagen in
patients with AS [33]. Such a cumulative shift to collagen I inmyocardial
content may underlie a higher myocardial stiffness and its func-
tional deteriorations which are typical features of decompensatedhypertrophy and heart failure in the pressure-overloaded hearts [11,
13,16,18,33,34].
Collagen V is a ﬁbrillar collagen that is required for the normal for-
mation of collagen I ﬁbrils [35]. In line with such a function of collagen
V, the upregulation of collagen V in our AS patients, especially in those
Fig. 9. Thrombospondins (TSP) in themyocardium of patients with AS and controls. Immunoﬂuorescent images of TSP1myocardial expression (green) in a control (upper left panel) and
in a AS-3 patient (middle left panel). Cardiomyocytes are stained red with phalloidin. Representative WB for TSP1, TSP2 and TSP4 and their quantiﬁcation.
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deposition of collagen I that is a typical feature of HF [25].
Non-ﬁbrillar collagens IV and VI were found in enhanced levels
in our AS patients. Collagen IV is a main component of the basement
membrane. Type VI collagen interacts with type IV creating an anchor-
ing bridge between the basementmembrane and the interstitialmatrix.
Collagen VI acts as an adhesive structure and interacts with other ECM
components including type I collagen and ﬁbronectin. It has recently
been demonstrated that ablation of the collagenVI genehas a protective
effect after myocardial infarction. Collagen VI disruption in these exper-
imental models reduced aberrant ECM remodeling and ﬁbrosis leading
to preservation of cardiac function [21]. Therefore, the upregulation of
collagenVI observed in our AS patientsmay reﬂect an activation of com-
pensatory cardioprotective mechanisms.
BMP1 is the enzyme that cleaves the C-terminal propeptides from
procollagen type I, III and V and is regarded therefore a determinant
event in collagen deposition. An elevation of BMP1 level in AS patients
shows that HF progression is characterized by an intensive ECM remod-
elling and collagen deposition.Observed downregulation of RECK in patients with decompensated
hypertrophy can be of negative importance, because RECK acting as a
MMPs inhibitor protects ﬁbrillar collagens from degradation and there-
fore maintains myocardial ﬁbrosis [36].
4.3. Matricellular proteins
In the present study, we found that tenascins showed a low expres-
sion in the control, whereas in all AS patients were signiﬁcantly in-
creased and therefore can be recommended as early tissue markers of
cardiac remodelling.
Thrombospondins (TSPs) are ECM proteins that inﬂuence collagen
ﬁbril assembly and contribute to regulation of ﬁbril formation, diameter
and uniformity [37]. In addition, TSPs bind to collagens and affect colla-
gen turnover and collagen ﬁbril organization [38,39]. The family of TSPs
consists of ﬁve members, where TSP1 and TSP2 are the most studied
and belong to matricellular proteins. TSP1 can modulate a variety of
cellular events in ECM and namely TSP1 is a crucial activator of TGFβ1,
inhibits angiogenesis and modulates MMP expression and activity,
Fig. 10.Matricelullar CTGF in cardiac remodeling. Representative immunoﬂuorescent pictures of CTGF (green) in a control patient (upper left panel) and in a patient with AS-III (upper
right panel). Cardiomyocytes are stained red with phalloidin, nuclei are stained blue with DAPI. QIF analysis of CTGF expressed as percent per tissue area in the study groups (lower
left panel). Representative WB and quantitative data of CTGF (lower right panel). All WB data are normalized to actin.
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was found to be induced in patients after myocardial infarction [41] or
in pressure-overloaded myocardium [42]. In our study the expression
of TSP1 was almost absent in control and was extremely increased in
AS patients, especially in those with decompensated hypertrophy. In
contrast to TSP1, TSP2 does not activate TGFβ1 and is more important
for controlling angiogenesis and integrity of newly formed matrix by
means of induction of increased collagen synthesis and inhibition of
its degradation [29]. An enhanced level of TSP2 mRNA was identiﬁed
in rats and humans with LV hypertrophy [42]. We observed an upregu-
lation of TSP2 during the transition from compensated (the AS-2 group)
to decompensated hypertrophy (the AS-3 group) suggesting the role of
TSP2 in promoting ﬁbrosis by increasing collagen synthesis.
TSP4 is a pentameric protein of the TSPs family that does not contain
procollagen homology domain. TSP4 modulates the proliferation of
endothelial and smooth muscle cells [43] and is highly expressed in
the adult human heart [38]. TSP4 appears to inhibit ﬁbrotic response
given that TSP4 null mice had increased collagen deposition in the
pressure-overloaded heart [10]. In addition, mRNA levels and gene ex-
pression of TSP4were found to bemarkedly upregulated in experimen-
tal pressure overload andmyocardial infarction in rats [44,45]. Our data
demonstrating remarkably increased expression levels of the TSP4 in
decompensated hypertrophy due to AS are in contrast with such obser-
vations and suggest that TSP4 might serve as a compensatory mecha-
nism to overwhelm myocardial ﬁbrosis in human patients.
Osteopontin can modulate a variety of cellular activities associated
with ﬁbrotic responses [46]. It has been shown that osteopontin is in-
creased in cardiac hypertrophy andmodulates cardiac ﬁbrosis probably
through the modulation of cellular adhesion and proliferation [47]. Ac-
cording to experimental data, osteopontin may be cleaved by MMPsand functioning thus as a cytokine being more active than the native
osteopontin [41]. Osteopontin has been shown to interact with collagen
types I, III, V andVI, and it is supposed to play a crucial role in atheroscle-
rosis, valvular stenosis, hypertrophy, myocardial infarction and HF [48].
Increased levels of osteopontinwere associatedwithHF aftermyocardi-
al infarction. In our study both, intact osteopontin and osteopontin
cleaved by MMP were upregulated in all AS patients indicating that
these proteins are reliable markers of the ECM remodeling and AS
severity.
Osteonectin is amatricellular protein taking part in collagen produc-
tion and deposition [49]. Although there are some indications to suggest
the role of osteonectin in procollagen processing after myocardial in-
farction or in pressure-overload mice models [50], we did not ﬁnd any
signiﬁcant differences between theAS groups in the osteonectin expres-
sion indicating that in human patients the role of osteonectin in ECM re-
modeling is negligible.
CTGF is anothermatricellular protein that is abundantly expressed in
the neonatal heart [51]. In the adult heart, CTGF expression becomes re-
stricted to the atria and large vessels in the adult heart [52]. Biological
functions of CTGF include stimulation of ﬁbrosis and ECM production
[53]. As a TGFβ inducible protein, CTGFmay contribute to the pathogen-
esis of ﬁbrosis by accentuating TGFβ-mediating actions. CTGF in turn
enhances TGFβ signalling leading thus to detrimental ECM accumula-
tion, myocardial ﬁbrosis and cardiac dysfunction.We have reported en-
hanced CTGF levels in patients with HF, in myocardial infarction and in
myocarditis [25]. Increased CTGFmRNAwas demonstrated in a rat pres-
sure overloadmodel [54]. In the present study, we have found increased
levels of CTGF only in decompensated hypertrophy. Taken together, our
data, as well as recent ﬁndings that patients with chronic HF patients
have increased plasma levels of CTGF which correlate with BNP, TGFβ
Fig. 11. Representative WB and quantitative data of TGFβ1, 2, 3 and their signaling proteins Smad1, 2, 3, 7 and TAK1. All WB data are normalized to actin.
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marker for cardiac dysfunction in HF.
4.4. Proﬁbrotic and anti-ﬁbrotic regulatory factors
TGFβ, a multifunctional peptide growth factor, exists in three highly
conserved isoforms: TGFβ1, TGFβ2, andTGFβ3. TGFβ isoforms showdif-
ferent heart tissue distributions and it is believed to affect different cell
types [55,56]. Most of studies have focused on TGFβ1 [7,57]. The data
concerning the role of TGFβ2 and TGFβ3 isoforms are contradictory. It
was found that TGFβ2 and TGFβ3 possess an anti-ﬁbrotic activity [58]
and that TGFβ-3 has a beneﬁcial effect on scar formation [59]. In the
present study we showed upregulation of TGFβ1 and downregulation
of TGFβ3 only in decompensated hypertrophy suggesting that TGFβ1
and TGFβ3 may counteract and it is also tempting to speculate thatmost probably the balance of TGFβ1/TGFβ3 determines the clinical out-
come and their ratio has a promising prognostic potential.
Activation of Smads by TGFβ is related to detrimental cardiac re-
modeling and progression to HF. According to experimental data,
TGFβ/Smad signaling contributes to an enhancement of cardiac ﬁbrosis
[60]. In our recent study we have demonstrated that TGFβ1 and Smad3
play an important role in ﬁbrosis progression in patients with atrial ﬁ-
brillation [24]. The present study showing upregulations of Smad2 and
Smad3 indicates the role of this signaling pathway in AS and conﬁrms
previous experimental and clinical data. In addition a proﬁbrotic action
of TGFβ1 via Smad2/3 was associated with Smad7 downregulation, in-
dicating a decrease of inhibitory Smads effects. Moreover, TAK1 and
Smad1/5/8 signaling pathways seem not to be activated in AS patients,
since we did not ﬁnd any upregulation of TAK1 and Smad 1 (Fig. 11) or
Smad 5 and 8 (data not shown). Indeed, our data show that TAK1
Fig. 12.RepresentativeWB and quantitative data of TNFα and TNFα receptors. AllWBdata
are normalized to actin.
Table 4
Summary of results.
Parameter Compensated
hypertrophy
(AS-1)
Transition
phase
(AS-2)
Decompensated
hypertrophy
(AS-3)
Collagen I + ++ +++
Collagen III ++ ++ ++
Collagen III/Collagen I ratio n −− −−
Collagen V n n +
Collagen IV n n +
Collagen VI n + ++
PINP n ++ +++
ICTP ++ + n
PIIINP ++ + n
IIINT n ++ +++
BMP1 +++ +++ +++
RECK n n −
Osteonectin n n n
Osteopontin + + +
Tenascin + ++ +++
Tenascin C + ++ +++
TSP1 n + +++
TSP2 n +++ +++
TSP4 n n +++
CTGF n n ++
TGFβ1 n n +
TGFβ2 n n n
TGFβ3 n n ++
TAK1 n n −−
Smad 1 n + ++
Smad 2 n + ++
Smad 3 + ++ +++
Smad 7 n n −
TNFα n −− −−
TNFα-R1 + ++ ++
TNFα-R2 n n ++
Changes in comparison with control values: n, unchanged;+, mildly increased;+++,
moderately increased; +++, severely increased; −, mildly decreased; –, moderately
decreased.
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ment of HF. Given that TAK1 may exert paradoxical anti-ﬁbrotic effects
[61,62], our data suggest that diminished TAK1 expression may sustain
progressive development of myocardial ﬁbrosis in AS patients.The downregulation of TNFα found in our AS patients is most
probably connected with a decrease of its anti-ﬁbrotic action, given
that TNFα activates MMPs and inhibits the expression of its inhibitors
[63,64]. TNFα exerts its effects by binding to the speciﬁc receptors
TNFα-R1 and TNFα-R2. The pro-ﬁbrotic effects of TNFα signaling in
myocardium appear to be due to interactions involving the TNFα-R1.
In contrast, TNFα-R2 signaling may reduce ﬁbrosis [31]. In the present
studywe found an increase in TNFα receptors in AS patients suggesting
their protective functions during HF progression, given that TNFα-R1
and TNFα-R2 are able to bind ligands serving thereby as “biological
buffers” neutralizing the activities of TNFα [31].5. Study limitations
The ﬁndings of the present study should be interpreted in light of
certain limitations. As for ethical reasons only myocardial samples
were retrieved from the interventricular septum. Therefore, it cannot
be excluded that the observed distinct features of ECM remodelling in
different AS groups are representative of thewhole ventricle. Neverthe-
less, many our observations concurwell with the results obtained in nu-
merous experimental model of aortic banding which have investigated
the entire LV [10–14]. Another limitation pertains to the remarkable
changes observed in the AS-3 group (decompensated LV hypertrophy
andHF). Due to the small cohort size of this group of patients we cannot
fully rule out an overlap between end-stage HF due to aortic valve dis-
ease and a primary cardiomyopathy.
In addition, virtually little is known whether myocardial ECM re-
modeling is similar to ECM remodelling of the aortic cusps as previously
reported [65,66] and reviewed in [9,67].
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Aortic valve replacement remains the most effective treatment of
chronic pressure overload secondary to aortic valve stenosis. Detection
of the structural and molecular components involved in myocardial
ECM remodeling could therefore help to ﬁnd promising therapeutic tar-
gets and prospective biomarkers to optimize the time of aortic valve re-
placement. The results of the present study may further stimulate
studies to identify serum levels of ﬁbrosis regulators in LV hypertrophy.
Whereas circulating biomarkers related to collagen synthesis and deg-
radation have increasingly been used to monitor myocardial ECM re-
modelling in diverse cardiac diseases (reviewed in [68,69]), more ECM
biomarkers are needed to explore. For example, myocardial
expression levels of TGFβ1 and BMP1 which were investigated in the
present study were quantiﬁed in the serum of patients with aortic ste-
nosis or in patients with HF and have demonstrated their plausibility
as non-invasive markers of ﬁbrosis [70,71]. In addition, our ﬁndings of
increased levels of myocardial tenascin C and its correlation with the
severity of AS and HF progression are in good accordance with quantiﬁ-
cations of circulating tenascin C in HF patients [72]. Based on our study,
CTGF represents a promising new circulating ECMbiomarkerwhichwas
recently documented in patients with atrial ﬁbrillation [73] or in pa-
tients with liver diseases developing ﬁbrosis [74].
7. Conclusions
Our ﬁndings indicate distinct changes in collagen deposition and
metabolism, differences in the expression of matricellular proteins,
TGF-β signaling, TNF-α and its receptors which are involved in the tran-
sition from compensated to decompensated LV hypertrophy and HF in
human patients with AS.
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